-
- 李侗曾副主任医师
-
医院:
首都医科大学附属北京佑安医院
科室:
综合感染科
- Q 热(羊流感)
- 狂犬病暴露后预防
- 霍乱诊疗常规
- 麻疹
- 眼泪或为艾滋病传播新途径 专家...
- 李兰娟:《柳叶刀》人感染禽源性...
- 《人类感染活禽市场来源的新发H...
- 第二例被治愈的艾滋病感染者
- 艾滋病将要被治愈?
- 霍乱诊疗常规
- 布氏杆菌病诊疗常规
- 手足口2012
- 艾滋病实名检测之我见
- 艾滋病---抗病毒治疗可以减少...
- 关于柳叶刀一篇HIV-N亚型个...
- 艾滋病合并结核时---尽快抗病...
- CD4细胞计数的意义?
- 共享性伴侣是导致 HIV 发生...
- HIV药物导致未老先衰
- 为什么有半年甚至一年窗口期的说...
- 医生的严谨和随意
- 初筛阳性,确证阴性
- 未知病毒之我见
- HCV诊治指南
- 艾滋病HAART治疗免疫重建炎...
- 欧洲肝脏研究学会《丙型肝炎诊疗...
- 尽早开始抗逆转录病毒治疗可以减...
- 恐艾者分型分期,你是哪型哪期?
- 关于HIV检测
- 关于抗体阴性感染者文献
- 博茨瓦纳一例抗体阴性的HIV-...
- 观看电影《盗梦空间》后的感想,...
- 中国医生面临威胁(Lancet...
- CD4达到100以上就可以停用...
- 手足口病最严重的情况
- 转卫生部手足口知识问答
- 麻疹(五)宝宝8个月时接种麻疹...
- 麻疹(四)今年麻疹为什么这么多
- Q热(羊流感)临床表现多样
- Q 热(羊流感)
- 关于原发性胆汁性肝硬化
- 我院年龄最小的呼吸机支持患儿顺...
- 特殊人群如何降低自己在甲型H1...
- 甲型H1N1流感感染者任何年龄...
- 甲型H1N1流感诊疗方案(第三...
- 转帖:关于HIV-1 O/N的...
- 关于HIV的O,N ,M亚群检...
- 美国研究者称艾滋病有望被治愈
- 全球艾滋病防控已经取得重大进步
- 新英格兰医学杂志论文:人类出现...
- 美国感染A/H1N1流感可能已...
- 合并其它疾病可能是猪流感致死的...
- 什么是猪流感(Swine fl...
- HIV感染者开始抗病毒治疗的时...
- HIV毒性正在增加?
- 又一项艾滋病疫苗研制计划受阻
- 作者:李侗曾|发布时间:2013-06-20|浏览量:1101次
美国国家卫生研究院(NIH)2013年4月25日宣布,一项进行到2b期的艾滋病疫苗研究计划因不能预防艾滋病传播,也不能减少感染者病毒载量而被宣布失败而搁置,
A HIV Vaccine Study Halted Due to Failure to Prevent Infection
US government–funded phase 2b study of an experimental HIV vaccine has been shut down because the vaccine did not prevent HIV infection or reduce viral load among vaccine recipients who became infected with HIV, the National Institutes of Health (NIH) announced April 25.
The vaccine's failure came to light during a scheduled interim data review by an independent data and safety monitoring board (DSMB), the agency said.
The vaccine consists of a 2-part regimen that includes a single recombinant DNA-based vaccine, delivered in a series of 3 immunizations over the course of 8 weeks to prime the immune system, followed by a single recombinant vaccine administered at 24 weeks as a booster vaccine. The booster vaccine contains a weakened adenovirus type 5 to carry the vaccine contents and stimulate the immune system.
The National Institute of Allergy and Infectious Disease (NIAID)-funded HIV Vaccine Trials Network (HVTN) 505 Study began in June 2009, as reported by Medscape Medical News.
The study population consisted of men who have sex with men and transgender people who have sex with men. A total of 2504 participants were enrolled at 21 sites in 19 US cities.
In its April 22 interim review, the DSMB examined data on 1250 participants who received the vaccine regimen and 1244 who received a placebo vaccine. The primary analysis looked at participants who were diagnosed with HIV infection after having been in the study a minimum of 28 weeks. In this analysis, HIV infection occurred in 27 vaccine recipients and 21 placebo vaccine recipients.
Overall, from the day of enrollment through the month 24 study visit, there were 41 cases of HIV infection in experimental vaccine recipients and 30 in placebo vaccine recipients, the NIH said.
The interim analysis also found that the experimental vaccine failed to reduce viral load among those who acquired HIV infection at least 28 weeks after entering the study and who had been followed-up for at least 20 weeks after diagnosis. There were 30 participants with measurable viral load (15 vaccine recipients; 15 placebo recipients).
"Based on these findings, the DSMB recommended that no further vaccinations with the investigational vaccine regimen be administered. As the trial's sponsor, NIAID concurred with the DSMB's recommendation and has instructed all HVTN 505 study sites to immediately cease administering injections but continue follow-up with study participants to further evaluate the trial data," the NIH said.
At this point, it is not clear why there was a non–statistically significant increase in HIV acquisition among participants in the investigational vaccine group compared with those in the placebo group, and further analysis is needed to draw any firm conclusions, the NIH said. The study team will continue to follow-up all study participants for 5 years from the time of enrollment.
Study investigators at each of the 21 clinical trial sites have been notified of the decision to stop the study, and study participants are being asked to report to their specific clinic sites during the next few weeks to find out whether they received the investigational vaccine or placebo.
"NIAID and the HVTN 505 study team are working to thoroughly analyze the study data to better understand why the vaccine did not work and to guide future vaccine development efforts. Detailed scientific findings will be made publicly available as soon as possible," the NIH said.
TA的其他文章: